Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a phase II efficacy (indicates the capacity for beneficial change or therapeutic
effect) and safety study of Dasatinib in patients with relapsed Chronic Myeloid Leukemia
(CML) following a Stem Cell Transplant (SCT) and who are not benefiting from other treatment,
such as imatinib therapy.
A relapse is when an illness that has seemed to be getting better, or to have been cured,
comes back or gets worse again.
A total of 50 patients ≥18 years of age will be registered on the trial.
Phase:
Phase 2
Details
Lead Sponsor:
European Group for Blood and Marrow Transplantation European Society for Blood and Marrow Transplantation